Apotex has settled patent litigation over Vascepa with Amarin, providing the generics firm with a guaranteed launch date in 2029.
Apotex has settled with Amarin over its generic version of the originator’s Vascepa (icosapent ethyl) in the US, providing a guaranteed launch date of 9 August 2029.
The date matches that agreed by Amarin with Teva in a separate settlement deal struck two years ago, in...
Lupin is planning to expand its footprint in China through a deal for a tiotropium dry powder inhaler with local player Sino Universal Pharmaceuticals.
As Endo and Mallinckrodt continue to work towards consummating the merger they announced earlier this year, the pair have revealed further organizational details of their combined generics and sterile injectables business, which is set to be spun off after the merger is complete.
Stephan Eder has left Stada and stepped down as president of Medicines for Europe, with the company announcing plans for his replacement and the association naming Polpharma CEO Markus Sieger as the association’s new interim president.
